Idebenone + Placebo
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leber's Hereditary Optic Neuropathy
Conditions
Leber's Hereditary Optic Neuropathy
Trial Timeline
— → —
NCT ID
NCT01495715About Idebenone + Placebo
Idebenone + Placebo is a phase 3 stage product being developed by Santhera Pharmaceuticals for Leber's Hereditary Optic Neuropathy. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01495715. Target conditions include Leber's Hereditary Optic Neuropathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01495715 | Phase 3 | Withdrawn |
| NCT01303406 | Phase 3 | Completed |
| NCT00747487 | Phase 2 | Completed |
| NCT00905268 | Phase 3 | Completed |
| NCT00654784 | Phase 2 | Completed |
Competing Products
4 competing products in Leber's Hereditary Optic Neuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 2 | 44 |
| Idebenone | Santhera Pharmaceuticals | Approved | 77 |
| Idebenone 150 MG Oral Tablet | Santhera Pharmaceuticals | Pre-clinical | 15 |
| Idebenone | Santhera Pharmaceuticals | Pre-clinical | 15 |